Drugs / Quadrivalent Recombinant Seasonal Influenza Vaccine
Quadrivalent Recombinant Seasonal Influenza Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03058692 | Apr 2018 → Jan 2019 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05945485 Comparator | Oct 2023 → May 2026 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Recombinant Seasonal Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05945485 ↗ |
| Modality | Vaccine | “The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses” NCT05945485 ↗ |
| Route | Intramuscular | “administered intramuscularly to the upper arm/deltoid once” NCT05945485 ↗ |